A Placebo Controlled Double- Blind Randomized Control Study To Assess The Efficacy And Safety Of Oral Losartan In The Treatment Of Recessive Dystrophic Epidermolysis Bullosa

PGIMER0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1.Recessive dystrophic epidermolysis bullosa patients regardless of sex.
•2.Patients of age 6 years and above
•3.Patients who are normotensive or hypertensive (cause other than renal stenosis)
•4.Patients with normal renal function, liver function and serum potassium levels.
•5.Patients who can give valid consent.
•6.Willing for monthly follow-up visits for at least 6 months.

•1.Dominant dystrophic epidermolysis bullosa, epidermolysis bullosa simplex, junctional epidermolysis bullosa and kindler syndrome
•2.High levels of potassium in the blood.
•3.Hypotension (defined as age- related systolic blood pressure under the 5th percentile)
•4.Hypersensitivity to losartan
•5.Kidney impairment with eGFR less than <30ml/ min
•6.Renal artery stenosis.
•7.Deranged liver function tests.
•8.Patients who are HBsAg, Anti HCV and HIV positive.
•9.Patients who are taking medicines which are likely to cause interactions like ACE inhibitors, Rifampicin
•10.Current pregnancy or nursing period
•11.Inability to come for monthly follow up visits for 6 months
•12.Those who donâ??t provide consent for the study

发起方